167 related articles for article (PubMed ID: 37271306)
21. Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test.
Schmid K; Fink K; Holl RW; Hebestreit H; Ballmann M
J Cyst Fibros; 2014 Jan; 13(1):80-5. PubMed ID: 23809507
[TBL] [Abstract][Full Text] [Related]
22. Cystic Fibrosis-Related Diabetes in Children: An Update.
Kim RJ
Pediatr Ann; 2016 Sep; 45(9):e321-6. PubMed ID: 27622916
[TBL] [Abstract][Full Text] [Related]
23. The course of glucose intolerance in children with cystic fibrosis: a retrospective study - preliminary report.
Piechowiak K; Trippenbach-Dulska H; Walicka-Serzysko K
Dev Period Med; 2015; 19(1):80-91. PubMed ID: 26003073
[TBL] [Abstract][Full Text] [Related]
24. [Screening and management of glucose metabolism disorders in cystic fibrosis patients. Practices survey in 4 French reference centers].
Haesebaert J; Bourdy S; Perceval M; Chabloz C; Nove-Josserand R; Reix P; Llerena C; Wion N; Touzet S
Arch Pediatr; 2009 Nov; 16(11):1435-42. PubMed ID: 19811898
[TBL] [Abstract][Full Text] [Related]
25. Combined Indeterminate and Impaired Glucose Tolerance Is a Novel Group at High Risk of Cystic Fibrosis-Related Diabetes.
Potter KJ; Reynaud Q; Boudreau V; Racine F; Tremblay F; Lavoie A; Carricart M; Mailhot G; Durieu I; Senior PA; Rabasa-Lhoret R
J Clin Endocrinol Metab; 2021 Sep; 106(10):e3901-e3910. PubMed ID: 34132785
[TBL] [Abstract][Full Text] [Related]
26. Canadian Cystic Fibrosis-related Diabetes Clinical Practice Survey: Analysis of Current Practices and Gaps in Clinical Care.
Potter KJ; Coriati A; Hicks P; Lands LC; McKinney ML; Boudreau V; Bonhoure A; Luca P; Ho J; Tagougui S; Jober A; Pohl M; Rosolowsky ET; Gilmour J; Lam GY; Stephenson AL; Senior PA; Rabasa-Lhoret R; Kherani T
Can J Diabetes; 2023 Apr; 47(3):263-271.e1. PubMed ID: 36872137
[TBL] [Abstract][Full Text] [Related]
27. Cystic-fibrosis related-diabetes (CFRD) is preceded by and associated with growth failure and deteriorating lung function.
Terliesner N; Vogel M; Steighardt A; Gausche R; Henn C; Hentschel J; Kapellen T; Klamt S; Gebhardt J; Kiess W; Prenzel F
J Pediatr Endocrinol Metab; 2017 Aug; 30(8):815-821. PubMed ID: 28245190
[TBL] [Abstract][Full Text] [Related]
28. Natural history of glucose intolerance in patients with cystic fibrosis: ten-year prospective observation program.
Sterescu AE; Rhodes B; Jackson R; Dupuis A; Hanna A; Wilson DC; Tullis E; Pencharz PB
J Pediatr; 2010 Apr; 156(4):613-7. PubMed ID: 19962154
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of Post-Glucose Challenge Hypoglycemia in Adult Patients With Cystic Fibrosis and Relevance to the Risk of Cystic Fibrosis-Related Diabetes.
Bonhoure A; Potter KJ; Reynaud Q; Boudreau V; Senior PA; Tremblay F; Lavoie A; Durieu I; Rabasa-Lhoret R
Can J Diabetes; 2022 Apr; 46(3):294-301.e2. PubMed ID: 35568431
[TBL] [Abstract][Full Text] [Related]
30. Screening for cystic fibrosis-related diabetes: a systematic review.
Waugh N; Royle P; Craigie I; Ho V; Pandit L; Ewings P; Adler A; Helms P; Sheldon C
Health Technol Assess; 2012; 16(24):iii-iv, 1-179. PubMed ID: 22572153
[TBL] [Abstract][Full Text] [Related]
31. Oral glucose tolerance test and continuous glucose monitoring to assess diabetes development in cystic fibrosis patients.
Clemente León M; Bilbao Gassó L; Moreno-Galdó A; Campos Martorrell A; Gartner Tizzano S; Yeste Fernández D; Carrascosa Lezcano A
Endocrinol Diabetes Nutr (Engl Ed); 2018 Jan; 65(1):45-51. PubMed ID: 29137964
[TBL] [Abstract][Full Text] [Related]
32. Glucose >200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes.
Taylor-Cousar JL; Janssen JS; Wilson A; Clair CG; Pickard KM; Jones MC; Brayshaw SJ; Chacon CS; Barboa CM; Sontag MK; Accurso FJ; Nichols DP; Saavedra MT; Nick JA
J Diabetes Res; 2016; 2016():1527932. PubMed ID: 27999822
[No Abstract] [Full Text] [Related]
33. Prevalence of hypoglycemia during oral glucose tolerance testing in adults with cystic fibrosis and risk of developing cystic fibrosis-related diabetes.
Mannik LA; Chang KA; Annoh PQK; Sykes J; Gilmour J; Robert R; Stephenson AL
J Cyst Fibros; 2018 Jul; 17(4):536-541. PubMed ID: 29680365
[TBL] [Abstract][Full Text] [Related]
34. Glucose intolerance in cystic fibrosis as a determinant of pulmonary function and clinical status.
Lavie M; Fisher D; Vilozni D; Forschmidt R; Sarouk I; Kanety H; Hemi R; Efrati O; Modan-Moses D
Diabetes Res Clin Pract; 2015 Dec; 110(3):276-84. PubMed ID: 26508676
[TBL] [Abstract][Full Text] [Related]
35. Glycemic control and FEV
Okoniewski W; Hughan KS; Weiner GA; Weiner DJ; Forno E
J Cyst Fibros; 2020 May; 19(3):460-465. PubMed ID: 31980357
[TBL] [Abstract][Full Text] [Related]
36. Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients.
Leclercq A; Gauthier B; Rosner V; Weiss L; Moreau F; Constantinescu AA; Kessler R; Kessler L
J Cyst Fibros; 2014 Jul; 13(4):478-84. PubMed ID: 24359972
[TBL] [Abstract][Full Text] [Related]
37. The use of fructosamine in cystic fibrosis-related diabetes (CFRD) screening.
Lam GY; Doll-Shankaruk M; Dayton J; Rodriguez-Capote K; Higgins TN; Thomas D; Mulchey K; Smith MP; Brown NE; Leung WM; Estey MP
J Cyst Fibros; 2018 Jan; 17(1):121-124. PubMed ID: 28648493
[TBL] [Abstract][Full Text] [Related]
38. The utility of glucose area under the curve from the oral glucose tolerance test as a screening tool for cystic fibrosis-related diabetes.
Gileles-Hillel A; Soesman LH; Miari S; Breuer O; Tsabari R; Elyashar-Earon H; Armoni S; Sprikkelman AB; Reiter J; Zangen D; Lavi E; Kerem E; Cohen-Cymberknoh M
Pediatr Pulmonol; 2022 Nov; 57(11):2774-2780. PubMed ID: 35999051
[TBL] [Abstract][Full Text] [Related]
39. Disposition index identifies defective beta-cell function in cystic fibrosis subjects with normal glucose tolerance.
Merjaneh L; He Q; Long Q; Phillips LS; Stecenko AA
J Cyst Fibros; 2015 Jan; 14(1):135-41. PubMed ID: 24998161
[TBL] [Abstract][Full Text] [Related]
40. Advances in cystic fibrosis-related diabetes: Current status and future directions.
Lurquin F; Buysschaert M; Preumont V
Diabetes Metab Syndr; 2023 Nov; 17(11):102899. PubMed ID: 37939435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
